Industry Strength Score
68/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
AN2 THERAPEUTICS INC (ANTX) Stock Price & Overview
NASDAQ:ANTX • US0373261058
Current stock price
4.68 USD
+0.13 (+2.86%)
At close:
4.68 USD
0 (0%)
After Hours:
The current stock price of ANTX is 4.68 USD. Today ANTX is up by 2.86%. In the past month the price increased by 43.12%. In the past year, price increased by 283.61%.
ANTX Key Statistics
52-Week Range1 - 6.9099
Current ANTX stock price positioned within its 52-week range.
1-Month Range2.872 - 5.11
Current ANTX stock price positioned within its 1-month range.
- Market Cap
- 168.199M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.16
- Dividend Yield
- N/A
ANTX Stock Performance
Today
+2.86%
1 Week
+7.83%
1 Month
+43.12%
3 Months
+314.16%
Longer-term
6 Months +280.49%
1 Year +283.61%
2 Years +135.18%
3 Years -16.58%
5 Years N/A
10 Years N/A
ANTX Stock Chart
ANTX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to ANTX. When comparing the yearly performance of all stocks, ANTX is one of the better performing stocks in the market, outperforming 99.09% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
ANTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ANTX. No worries on liquidiy or solvency for ANTX as it has an excellent financial health rating, but there are worries on the profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
ANTX Earnings
Next Earnings DateMay 13, 2026
Last Earnings DateMar 17, 2026
PeriodQ4 / 2025
EPS Reported-$0.29
Revenue Reported
EPS Surprise -18.46%
Revenue Surprise %
ANTX Forecast & Estimates
6 analysts have analysed ANTX and the average price target is 1.02 USD. This implies a price decrease of -78.21% is expected in the next year compared to the current price of 4.68.
Analysts
Analysts43.33
Price Target1.02 (-78.21%)
EPS Next Y19.98%
Revenue Next YearN/A
ANTX Index Membership
ANTX is currently included in the following stock indexes tracked on ChartMill.
ANTX Financial Highlights
Over the last trailing twelve months ANTX reported a non-GAAP Earnings per Share(EPS) of -1.16. The EPS increased by 29.27% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-35.17M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -56.78% | ||
| ROE | -66.29% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%-16%
Sales Q2Q%N/A
EPS 1Y (TTM)29.27%
Revenue 1Y (TTM)N/A
ANTX Ownership
Ownership
Inst Owners51.46%
Shares35.94M
Float28.56M
Ins Owners8.86%
Short Float %2.22%
Short Ratio0.36
ANTX Industry Overview
ANTX operates in the Pharmaceuticals sub-industry within the Health Care sector. This group contains 135 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
16/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
47%
Outperformed 47% of sub-industries
3 Month Rank
55%
Outperformed 55% of sub-industries
6 Month Rank
41%
Outperformed 41% of sub-industries
Industry Fundamentals & Breadth
- Members
- 135
- New Highs
- 5.2%
- New Lows
- 3%
- Average ROE
- 96.3%
- Average Profit Margin
- 29.8%
- Average Operating Margin
- 41.4%
- Average P/E
- 25.7
- Average Fwd P/E
- 17.8
- Average Debt/Equity
- 1.3
ANTX Competitors/Peers
The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 22.63 | 910.173B | ||
| JNJ | JOHNSON & JOHNSON | 17.91 | 547.212B | ||
| MRK | MERCK & CO. INC. | 11.43 | 277.022B | ||
| PFE | PFIZER INC | 8.81 | 149.775B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.41 | 118.87B | ||
| ZTS | ZOETIS INC | 16.14 | 48.007B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.57 | 28.541B | ||
| VTRS | VIATRIS INC | 6.03 | 17.513B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.39 | 11.241B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 10.564B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.109B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.809B | ||
| CORT | CORCEPT THERAPEUTICS INC | 35.54 | 5.47B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ANTX
Company Profile
AN2 Therapeutics, Inc. operates as a global health biopharmaceutical company. The company is headquartered in Menlo Park, California. The company went IPO on 2022-03-25. The firm is focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. Its initial candidate is epetraborole, which is a potential once-daily, oral treatment with a novel mechanism of action for patients with non-tuberculous mycobacterial (NTM) lung disease, a rare, chronic, and progressive infectious disease caused by bacteria known as mycobacteria, which leads to irreversible lung damage and can be fatal. Epetraborole is designed to produce broad-spectrum antimycobacterial activity through inhibition of an essential and universal step in bacterial protein synthesis. Epetraborole is an investigational, boron-containing, orally bioavailable, small molecule inhibitor of bacterial leucyl-tRNA synthetase (LeuRS), an enzyme that catalyzes the attachment of leucine to transfer RNA (tRNA), molecules, an essential step in protein synthesis.
Company Info
IPO: 2022-03-25
AN2 THERAPEUTICS INC
1300 El Camino Real, Suite 100
Menlo Park CALIFORNIA 90501 US
CEO: Robert Corrigan
Employees: 22
Phone: 16503319090
AN2 THERAPEUTICS INC / ANTX FAQ
What does ANTX do?
AN2 Therapeutics, Inc. operates as a global health biopharmaceutical company. The company is headquartered in Menlo Park, California. The company went IPO on 2022-03-25. The firm is focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. Its initial candidate is epetraborole, which is a potential once-daily, oral treatment with a novel mechanism of action for patients with non-tuberculous mycobacterial (NTM) lung disease, a rare, chronic, and progressive infectious disease caused by bacteria known as mycobacteria, which leads to irreversible lung damage and can be fatal. Epetraborole is designed to produce broad-spectrum antimycobacterial activity through inhibition of an essential and universal step in bacterial protein synthesis. Epetraborole is an investigational, boron-containing, orally bioavailable, small molecule inhibitor of bacterial leucyl-tRNA synthetase (LeuRS), an enzyme that catalyzes the attachment of leucine to transfer RNA (tRNA), molecules, an essential step in protein synthesis.
What is the current price of ANTX stock?
The current stock price of ANTX is 4.68 USD. The price increased by 2.86% in the last trading session.
What is the dividend status of AN2 THERAPEUTICS INC?
ANTX does not pay a dividend.
What is the ChartMill technical and fundamental rating of ANTX stock?
ANTX has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the short interest for ANTX stock?
The outstanding short interest for AN2 THERAPEUTICS INC (ANTX) is 2.22% of its float.